Dr José Nasser MD PHD Substack

Major Antineoplastic Mechanisms of Combination Ivermectin-Mebendazole

Recent preclinical analyses highlight the anticancer potential of combining ivermectin and mebendazole, two antiparasitic drugs repurposed for oncology. Ivermectin suppresses proliferative signaling pathways such as Wnt/β‑catenin, Akt/mTOR, and STAT3, while mebendazole disrupts microtubule polymerization, inducing G2/M arrest. Together they inhibit tumor cell proliferation, angiogenesis, and promote apoptosis, yielding an 84% net clinical benefit in a Wellness Company study. The findings illustrate a multi‑target strategy that could accelerate low‑cost cancer therapeutics.